DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy - DETECT
Study identifier:D6570R00001
ClinicalTrials.gov identifier:NCT02552160
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
3732
Study type
Observational
Age
40 Years +
Date
Study Start Date: 24 Sept 2015
Primary Completion Date: 31 Dec 2017
Study Completion Date: 31 Dec 2017
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: Open Label
Primary Purpose: -
Verification:
Verified 01 Dec 2018 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Patients on Duaklir® Genuair® Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol) | - |
| Patients on Ultibro® Breezhaler® Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) | - |
| Patients on Anoro® Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol) | - |
